New York, New York–(Newsfile Corp. – January 12, 2025) – WHY: The Rosen Law Firm, a global investor rights law firm, reminds purchasers of Humacyte, Inc.’s securities. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”), in material January 17, 2025 leads the plaintiff’s deadline.

WHATEVER: If you purchased Humacyte securities during the Class Period you may be entitled to compensation free of any out-of-pocket fees or expenses through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Humacyte class action, go to https://rosenlegal.com/submit-form/?case_id=31305 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has been filed. If you want to serve as the lead plaintiff, you must move the Court no later than January 17, 2025. A lead plaintiff is a representative party acting on behalf of other class members in the conduct of litigation.

WHY ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, the companies issuing the notices don’t have the same experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen who refer clients or partners to the law firms that actually litigate the cases. Be wise in choosing advice. The Rosen Law Firm represents investors worldwide, concentrating its practice in securities class actions and shareholder derivative litigation. The Rosen Law Firm achieved the largest securities class action settlement against a Chinese Company at that time. The Rosen Law Firm is ranked No. 1 in the ISS Securities Class action (WA:) Services for the number of securities class action settlements in 2017. The company has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the company earned over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, during the Class, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Humacyte’s Durham, North Carolina facility failed to follow good practices in manufacturing, including quality assurance and microbial testing. ; (2) the Food and Drug Administration’s (“FDA”) review of the Biologics License Application (“BLA”) will be delayed while Humacyte corrects these deficiencies; and (3) as a result, there is a significant risk to the FDA’s approval of the Acellular Tissue Engineered Vessel (“ATEV”) for vascular trauma; and (4) as a result of the foregoing, defendants’ positive statements about Humacyte’s business, operations, and prospects are materially misleading and/or without a reasonable basis. When the true details entered the market, the lawsuit claimed that investors suffered damages.

To join the Humacyte class action, go to https://rosenlegal.com/submit-form/?case_id=31305 or call Phillip Kim, Esq. toll free at 866-767-3653 or email [email protected] for class action information.

No Class Verified. Until a class is certified, you are not represented by counsel unless you hold one. You can choose the advice you want. You can also stay out of class and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent on serving as the lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https :// /www.facebook.com/rosenlawfirm/.

Attorney Advertising. The first results do not guarantee a similar result.

—————————-

To view the original version of this press release, please visit https://www.newsfilecorp.com/release/236924